Samantha A. Swenson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samantha A. Swenson has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Ricia Katherine Hyde
University of Nebraska Medical Center 1 Department of Biochemistry and Molecular Biology Omaha, Nebraska
20 shared publications - Sipra Panda
Department of Biochemistry and Molecular Biology, Omaha, USA
19 shared publications - Calvin Lam
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center
18 shared publications - Adrian R. Black
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
17 shared publications - Arjun Dhir
University of Nebraska Medical Center 1 Department of Biochemistry and Molecular Biology Omaha, Nebraska
17 shared publications - Arnob Mitro
University of Nebraska Medical Center 1 Department of Biochemistry and Molecular Biology Omaha, Nebraska
17 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (40) , 4317-4329
The Inv(16) Oncogene CBFB::MYH11 is Required for the Survival of Leukemia Cells in the Blood and Spleen, but not the Bone Marrow
Inversion of chromosome 16 [inv(16)] generates the fusion gene CBFB::MYH11 (CM) and is one of the most common chromosomal rearrangements in Acute Myeloid Leukemia (AML). Expression of CM is required for leukemia initiation. Patients with inv(16) at diagnosis invariably have the rearrangement at relapse, leading to the assumption that CM is also required after leukemic transformation. However, a role for CM in leukemia maintenance has yet to be shown experimentally. To address this, we used an inducible CM knockdown (KD) mouse model and found that decreased CM eliminated leukemia cells from the peripheral blood and spleen, but not the bone marrow, despite all populations exhibiting significantly decreased CM mRNA and protein. The surviving CM KD cells in the bone marrow showed decreased apoptosis and proliferation, and increased expression of autophagy related genes. Surprisingly, with prolonged KD of CM, ~40% of mice re-established disease despite maintaining decreased CM. Our work indicates that CM is required for leukemia survival in the spleen and peripheral blood, but in the bone marrow CM KD leukemia cells can survive and re-establish disease independent of the fusion protein. These findings imply that targeting CM alone has potential to reduce leukemic burden but not cure the disease.
- 17 August 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (40) , 4317-4329
Open AccessThe Inv(16) Oncogene CBFB::MYH11 is Required for the Survival of Leukemia Cells in the Blood and Spleen, but not the Bone Marrow
Inversion of chromosome 16 [inv(16)] generates the fusion gene CBFB::MYH11 (CM) and is one of the most common chromosomal rearrangements in Acute Myeloid Leukemia (AML). Expression of CM is required for leukemia initiation. Patients with inv(16) at diagnosis invariably have the rearrangement at relapse, leading to the assumption that CM is also required after leukemic transformation. However, a role for CM in leukemia maintenance has yet to be shown experimentally. To address this, we used an inducible CM knockdown (KD) mouse model and found that decreased CM eliminated leukemia cells from the peripheral blood and spleen, but not the bone marrow, despite all populations exhibiting significantly decreased CM mRNA and protein. The surviving CM KD cells in the bone marrow showed decreased apoptosis and proliferation, and increased expression of autophagy related genes. Surprisingly, with prolonged KD of CM, ~40% of mice re-established disease despite maintaining decreased CM. Our work indicates that CM is required for leukemia survival in the spleen and peripheral blood, but in the bone marrow CM KD leukemia cells can survive and re-establish disease independent of the fusion protein. These findings imply that targeting CM alone has potential to reduce leukemic burden but not cure the disease.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 2. PAMD-Ch17 blocks the CXCR4 receptor.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 2. PAMD-Ch17 blocks the CXCR4 receptor.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 1. Primary Patient Samples.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 1. Primary Patient Samples.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
PAMD-Ch17 is a polymer composed of the CXCR4 inhibitor AMD3100/Plerixafor with a cholesterol modification. In previous work, we showed that PAMD-Ch17, but not AMD3100, induces cell death and differentiation in mouse acute myeloid leukemia cells. To investigate the mechanism of PAMD-Ch17’s novel antileukemic effects, we tested PAMD-Ch17 against a panel of human leukemia cell lines and found that PAMD-Ch17 is effective against a variety of acute leukemias, with T-cell acute lymphoblastic leukemia (T-ALL) cell lines being highly sensitive. Surprisingly, CXCR4 knockout T-ALL cells were equally sensitive to PAMD-Ch17. Using a fluorescently tagged PAMD-Ch17, we found that the drug colocalized to mitochondria. We also found that PAMD-Ch17 induced changes in the expression of genes related to mitochondrial function, increased levels of mitochondrial superoxide, and decreased mitochondrial membrane potential. Using Seahorse assays, we found that PAMD-Ch17 decreased baseline oxygen consumption, ATP production, and proton leakage. In addition, we identified ATP synthase subunits as binding partners of PAMD-Ch17 and showed that the polymer, but not AMD3100, inhibited ATP synthase activity. In mouse primary T-ALL, but not healthy bone marrow cells, PAMD-Ch17 induced both mitochondrial superoxide and cell death. Using human bone marrow organoids, we found that PAMD-Ch17 induced mitochondrial superoxide and cell death in T-ALL cells from patients, but not in healthy stromal and hematopoietic cells. Collectively, our results indicate that PAMD-Ch17 has antileukemic effects against T-ALL cells but not healthy cells, likely mediated through a CXCR4-independent, mitochondrial-based mechanism. These findings support the further development of PAMDs as potential therapeutics for patients with T-ALL.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
PAMD-Ch17 is a polymer composed of the CXCR4 inhibitor AMD3100/Plerixafor with a cholesterol modification. In previous work, we showed that PAMD-Ch17, but not AMD3100, induces cell death and differentiation in mouse acute myeloid leukemia cells. To investigate the mechanism of PAMD-Ch17’s novel antileukemic effects, we tested PAMD-Ch17 against a panel of human leukemia cell lines and found that PAMD-Ch17 is effective against a variety of acute leukemias, with T-cell acute lymphoblastic leukemia (T-ALL) cell lines being highly sensitive. Surprisingly, CXCR4 knockout T-ALL cells were equally sensitive to PAMD-Ch17. Using a fluorescently tagged PAMD-Ch17, we found that the drug colocalized to mitochondria. We also found that PAMD-Ch17 induced changes in the expression of genes related to mitochondrial function, increased levels of mitochondrial superoxide, and decreased mitochondrial membrane potential. Using Seahorse assays, we found that PAMD-Ch17 decreased baseline oxygen consumption, ATP production, and proton leakage. In addition, we identified ATP synthase subunits as binding partners of PAMD-Ch17 and showed that the polymer, but not AMD3100, inhibited ATP synthase activity. In mouse primary T-ALL, but not healthy bone marrow cells, PAMD-Ch17 induced both mitochondrial superoxide and cell death. Using human bone marrow organoids, we found that PAMD-Ch17 induced mitochondrial superoxide and cell death in T-ALL cells from patients, but not in healthy stromal and hematopoietic cells. Collectively, our results indicate that PAMD-Ch17 has antileukemic effects against T-ALL cells but not healthy cells, likely mediated through a CXCR4-independent, mitochondrial-based mechanism. These findings support the further development of PAMDs as potential therapeutics for patients with T-ALL.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 5. PAMD-Ch17 dysregulates genes different from that of CXCR4 KO.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 5. PAMD-Ch17 dysregulates genes different from that of CXCR4 KO.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 10. PAMD-Ch17’s effect on human bone marrow organoids.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 10. PAMD-Ch17’s effect on human bone marrow organoids.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 4. PAMD-Ch17 induces differential expression of genes related to cholesterol biosynthesis, protein translation, and mitochondrial homeostasis.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 4. PAMD-Ch17 induces differential expression of genes related to cholesterol biosynthesis, protein translation, and mitochondrial homeostasis.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 11. Proposed Mechanism of PAMD-Ch17’s Anti-leukemic Effects.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 11. Proposed Mechanism of PAMD-Ch17’s Anti-leukemic Effects.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 6. PAMD-Ch17 colocalizes with the mitochondria.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Figure 6. PAMD-Ch17 colocalizes with the mitochondria.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 2. Differentially Expressed Gene lists.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4
Supplementary Table 2. Differentially Expressed Gene lists.